ACUTAAS CHEMICALS LIMITED Stock Price Today (NSE: ACUTAAS)
Fundamental Score
ACUTAAS CHEMICALS LIMITED Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ACUTAAS CHEMICALS LIMITED share price today is ₹2558.60, up +0.70% on NSE/BSE as of 30 March 2026. ACUTAAS CHEMICALS LIMITED (ACUTAAS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.53K (Cr). The 52-week high for ACUTAAS share price is ₹2580.00 and the 52-week low is ₹1059.00. At a P/E ratio of 64.86x, ACUTAAS is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.00% and a debt-to-equity ratio of 0.01.
ACUTAAS CHEMICALS LIMITED Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
ACUTAAS CHEMICALS LIMITED Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
ACUTAAS CHEMICALS Share Price: A ROCE-Driven Analysis
A crucial, often overlooked, aspect of the pharmaceutical industry is the efficient allocation of capital. Companies that can generate high returns on their capital employed are best positioned to navigate the sector's inherent R&D risks and regulatory hurdles. This analysis delves into the financial health of ACUTAAS CHEMICALS LIMITED, focusing particularly on its Return on Capital Employed (ROCE) and its implications for long-term value creation. Currently, the ACUTAAS CHEMICALS share price stands at ₹1986.900024, with a Price-to-Earnings (PE) ratio of 64.86 and a ROCE of 19.92%.
The cornerstone of this analysis is the company's ROCE of 19.92%. This figure suggests that for every rupee of capital employed in the business, ACUTAAS CHEMICALS is generating approximately 19.92 paise in profit. This level of ROCE is important, as it indicates the company's efficiency in using its resources to generate profits. A consistently high ROCE often contributes to building a robust economic moat, as it signals a competitive advantage within the pharmaceutical sector. This advantage might stem from efficient operations, strong pricing power, or proprietary technologies. The capacity to reinvest these returns further enhances the moat and fuels future growth.
Comparing ACUTAAS CHEMICALS LIMITED with its peers reveals a nuanced picture. While a direct comparative analysis requires more granular data, we can observe that differences in management quality, as perceived by the market, can significantly impact valuations. For instance,
Mankind Pharma Ltd might command a premium valuation due to perceived superior management and brand equity. The market's assessment of management competence plays a crucial role in evaluating the sustainability of a company's ROCE. A lower PE ratio relative to ROCE compared to peers might indicate an undervalued opportunity, or potential concerns about sustainability. The current PE of 64.86 suggests relatively high market expectations for ACUTAAS CHEMICALS LIMITED's future growth.This analysis considers only readily available financial data and provides an observational perspective on ACUTAAS CHEMICALS LIMITED's financial standing, particularly its ROCE. This examination is part of a broader 80-parameter fundamental audit, verified by Sweta Mishra, designed to provide a comprehensive overview of the company’s financial health and operational efficiency.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ACUTAAS CHEMICALS LIMITED Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ACUTAAS across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (16.00%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (19.92%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (20.91%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (93.52%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.10%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (33.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (41.40% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (120.69x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Institutional Confidence (FII+DII: 39.43%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 64.86x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-418.98 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
ACUTAAS CHEMICALS LIMITED Financial Statements
Comprehensive financial data for ACUTAAS CHEMICALS LIMITED including income statement, balance sheet and cash flow
About ACUTAAS (ACUTAAS CHEMICALS LIMITED)
ACUTAAS CHEMICALS LIMITED is a dynamic force in the pharmaceutical sector, dedicated to pioneering innovative solutions and driving advancements in healthcare. With a global vision... and a commitment to excellence, Acutaas focuses on the intricate realm of pharmaceutical intermediates, serving as a crucial bridge between research and the production of life-enhancing medications. The company's core strength lies in its state-of-the-art research and development infrastructure, enabling its team of expert scientists to develop cutting-edge intermediates with precision and efficiency. Acutaas takes pride in its ability to deliver high-quality products that meet the stringent requirements of the pharmaceutical industry, catering to the needs of both regulated and generic active pharmaceutical ingredients manufacturers worldwide. The company's extensive portfolio encompasses a diverse range of pharmaceutical intermediates carefully designed for critical therapeutic applications. Acutaas specializes in intermediates used in the synthesis of active pharmaceutical ingredients (APIs) that address a wide array of health challenges, including those related to viral infections, inflammation, mental health disorders, oncological diseases, neurological conditions, mood disorders, and blood clotting. The meticulous approach to quality control ensures that each intermediate meets the highest standards of purity, stability, and efficacy, thus facilitating the production of safe and effective medications. Acutaas is unwavering in its dedication to providing reliable and innovative solutions to its partners in the pharmaceutical industry. Beyond pharmaceuticals, ACUTAAS CHEMICALS LIMITED extends its expertise to specialty chemicals for diverse industries. The company's custom-designed specialty chemicals are used in cutting-edge battery technologies, enhancing the performance and longevity of energy storage solutions. They also formulate specialty chemicals for the personal care industry, providing unique ingredients for advanced cosmetic and skincare products. In the realm of agriculture, Acutaas develops specialized chemicals that improve crop yields and protect against pests. Moreover, Acutaas specialty chemicals enhance the durability, aesthetics, and performance of coatings, ensuring lasting protection and visual appeal. Committed to innovation, ACUTAAS CHEMICALS LIMITED strives to deliver comprehensive solutions that enhance performance across multiple sectors.
Company Details
Key Leadership
ACUTAAS Share Price: Frequently Asked Questions
What is the current share price of ACUTAAS CHEMICALS LIMITED (ACUTAAS)?
As of 30 Mar 2026, 12:07 pm IST, ACUTAAS CHEMICALS LIMITED share price is ₹2558.60. The ACUTAAS stock has a market capitalisation of ₹14.53K (Cr) on NSE/BSE.
Is ACUTAAS share price Overvalued or Undervalued?
ACUTAAS share price is currently trading at a P/E ratio of 64.86x, compared to the industry average of 31.77x. Based on this relative valuation, the ACUTAAS CHEMICALS LIMITED stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ACUTAAS share price?
The 52-week high of ACUTAAS share price is ₹2580.00 and the 52-week low is ₹1059.00. These values are updated daily from NSE/BSE price data.
What factors affect the ACUTAAS CHEMICALS LIMITED share price?
Key factors influencing ACUTAAS share price include quarterly earnings growth (Sales Growth: 24.10%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is ACUTAAS CHEMICALS LIMITED a good stock for long-term investment?
ACUTAAS CHEMICALS LIMITED shows a 5-year Profit Growth of 41.40% and an ROE of 16.00%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing in ACUTAAS shares.
How does ACUTAAS CHEMICALS LIMITED compare with its industry peers?
ACUTAAS CHEMICALS LIMITED competes with major peers in the Pharmaceuticals. Investors should compare ACUTAAS share price P/E of 64.86x and ROE of 16.00% against the industry averages to determine competitive standing.
What is the P/E ratio of ACUTAAS and what does it mean?
ACUTAAS share price has a P/E ratio of 64.86x compared to the industry average of 31.77x. Investors pay ₹65 for every ₹1 of annual earnings.
How is ACUTAAS performing according to Bull Run's analysis?
ACUTAAS has a Bull Run fundamental score of 64.1/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ACUTAAS belong to?
ACUTAAS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting ACUTAAS CHEMICALS LIMITED share price.
What is Return on Equity (ROE) and why is it important for ACUTAAS?
ACUTAAS has an ROE of 16.00%, which indicates excellent management efficiency. ROE measures how efficiently ACUTAAS CHEMICALS LIMITED generates profits from shareholders capital.
How is ACUTAAS debt-to-equity ratio and what does it indicate?
ACUTAAS has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk.
What is ACUTAAS dividend yield and is it a good dividend stock?
ACUTAAS offers a dividend yield of 0.08%, meaning you receive ₹0.08 annual dividend for every ₹100 invested in ACUTAAS CHEMICALS LIMITED shares.
How has ACUTAAS share price grown over the past 5 years?
ACUTAAS has achieved 5-year growth rates of: Sales Growth 33.26%, Profit Growth 41.40%, and EPS Growth 7.70%.
What is the promoter holding in ACUTAAS and why does it matter?
Promoters hold 32.66% of ACUTAAS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in ACUTAAS CHEMICALS LIMITED.
What is ACUTAAS market capitalisation category?
ACUTAAS has a market capitalisation of ₹14526 crores, placing it in the Mid-cap category.
How volatile is ACUTAAS stock?
ACUTAAS has a beta of N/A. A beta > 1 suggests the ACUTAAS CHEMICALS LIMITED stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ACUTAAS operating profit margin trend?
ACUTAAS has a 5-year average Operating Profit Margin (OPM) of 20.91%, indicating the company's operational efficiency.
How is ACUTAAS quarterly performance?
Recent quarterly performance shows ACUTAAS CHEMICALS LIMITED YoY Sales Growth of 24.10% and YoY Profit Growth of 93.52%.
What is the institutional holding pattern in ACUTAAS?
ACUTAAS has FII holding of 16.84% and DII holding of 22.59%. Significant institutional holding often suggests professional confidence in the ACUTAAS CHEMICALS LIMITED stock.